Wellington Management Group LLP Has $1.13 Million Stock Position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS)

Wellington Management Group LLP increased its stake in Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) by 43.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 91,529 shares of the company's stock after buying an additional 27,531 shares during the period. Wellington Management Group LLP owned about 0.18% of Mineralys Therapeutics worth $1,127,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. increased its position in shares of Mineralys Therapeutics by 4.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 213,599 shares of the company's stock worth $2,587,000 after purchasing an additional 9,664 shares during the last quarter. State Street Corp lifted its holdings in Mineralys Therapeutics by 4.0% during the 3rd quarter. State Street Corp now owns 483,766 shares of the company's stock worth $5,858,000 after buying an additional 18,627 shares during the last quarter. Barclays PLC lifted its holdings in Mineralys Therapeutics by 281.8% during the 3rd quarter. Barclays PLC now owns 38,218 shares of the company's stock worth $463,000 after buying an additional 28,208 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Mineralys Therapeutics by 6.6% in the 3rd quarter. Geode Capital Management LLC now owns 620,853 shares of the company's stock worth $7,520,000 after acquiring an additional 38,527 shares in the last quarter. Finally, Franklin Resources Inc. raised its position in shares of Mineralys Therapeutics by 17.7% during the 3rd quarter. Franklin Resources Inc. now owns 1,745,513 shares of the company's stock valued at $21,138,000 after acquiring an additional 262,922 shares in the last quarter. 84.46% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Mineralys Therapeutics Stock Performance

Shares of NASDAQ:MLYS traded down $0.04 during trading hours on Tuesday, hitting $13.88. The stock had a trading volume of 440,438 shares, compared to its average volume of 413,614. The stock's fifty day simple moving average is $12.29 and its 200 day simple moving average is $12.33. The firm has a market capitalization of $871.46 million, a price-to-earnings ratio of -3.81 and a beta of -0.39. Mineralys Therapeutics, Inc. has a 1-year low of $8.24 and a 1-year high of $18.38.

Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last announced its earnings results on Wednesday, February 12th. The company reported ($0.98) earnings per share for the quarter, beating the consensus estimate of ($1.00) by $0.02. As a group, research analysts anticipate that Mineralys Therapeutics, Inc. will post -4.23 EPS for the current year.

Analyst Ratings Changes

MLYS has been the subject of several recent research reports. The Goldman Sachs Group lowered their target price on shares of Mineralys Therapeutics from $28.00 to $24.00 and set a "buy" rating for the company in a research note on Thursday, February 13th. HC Wainwright raised their target price on shares of Mineralys Therapeutics from $30.00 to $42.00 and gave the stock a "buy" rating in a report on Wednesday, April 2nd. Finally, Guggenheim reaffirmed a "buy" rating on shares of Mineralys Therapeutics in a report on Monday, February 24th.

Insider Buying and Selling

In other Mineralys Therapeutics news, CEO Jon Congleton sold 15,319 shares of the company's stock in a transaction dated Friday, April 11th. The shares were sold at an average price of $12.19, for a total value of $186,738.61. Following the completion of the sale, the chief executive officer now directly owns 862,289 shares of the company's stock, valued at approximately $10,511,302.91. This represents a 1.75 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Ra Capital Management, L.P. acquired 1,296,296 shares of the stock in a transaction dated Thursday, March 13th. The stock was acquired at an average cost of $13.50 per share, for a total transaction of $17,499,996.00. Following the purchase, the director now directly owns 4,280,051 shares in the company, valued at approximately $57,780,688.50. The trade was a 43.45 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 33.24% of the company's stock.

Mineralys Therapeutics Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.